KLF 15 Works as an Early Anti-Fibrotic Transcriptional Regulator in Ang II-Induced Renal Fibrosis via Down-Regulation of CTGF Expression

Background/Aims: Angiotensin II (Ang II) has been regarded as an important profibrogenic cytokine in renal fibrosis. Krüppel-like factor 15 (KLF15) has been identified as an important negative transcription factor in renal fibrosis. However, little is known about the role of KLF15 in Ang II-induced renal fibrosis. Methods: In this study, we randomized mice into a control group, Ang II group or Ang II plus losartan group. KLF15 expression was examined with real-time PCR and immunofluorescence in these groups. In vitro, KLF15 expression was examined by Western blot in rat renal fibroblasts (NRK-49F) stimulated with Ang II, and the effect of altered KLF15 expression on the regulation of the profibrotic factor connective tissue growth factor (CTGF) was further explored with co-immunoprecipitation (CoIP) and chromatin immunoprecipitation (ChIP) analyses. Results: Compared with the control group, the murine model of Ang II-induced renal fibrosis demonstrated a significant decrease in renal KLF15 expression at 4 weeks and presented with progressive renal fibrosis at 6 weeks. Meanwhile, losartan, an angiotensin type 1 (AT1) receptor antagonist, effectively prevented the down-regulation of KLF15 expression induced by Ang II infusion. In vitro, NRK-49F cells stimulated with Ang II exhibited a significant decrease in KLF15 expression, accompanied by a marked increase in the expression of profibrotic factors and in the production of extracellular matrix. The up-regulation of CTGF expression induced by Ang II stimulation was inhibited by KLF15 overexpression in NRK-49F cells, and losartan treatment prevented the down-regulation of KLF15 expression and the up-regulation of CTGF expression induced by Ang II stimulation. Furthermore, CoIP and ChIP assays revealed that the transcription regulator KLF15 directly bound to the co-activator P/CAF and repressed its recruitment to the CTGF promoter. Conclusions: Ang II down-regulates KLF15 expression via the AT1 receptor, and KLF15 is likely to inhibit Ang II-induced CTGF expression by repressing the recruitment of the co-activator P/CAF to the CTGF promoter.

[1]  Y. Chang,et al.  Co-inhibition of Angiotensin II Receptor and Endothelin-1 Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice , 2016, Kidney and Blood Pressure Research.

[2]  Bo Zhang,et al.  Angiotensin-Converting Enzyme Inhibitor (ACEI)-Mediated Amelioration in Renal Fibrosis Involves Suppression of Mast Cell Degranulation , 2016, Kidney and Blood Pressure Research.

[3]  B. Li,et al.  Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy , 2015, Journal of diabetes research.

[4]  Z. Meng,et al.  Ets-1 upregulation mediates angiotensin II-related cardiac fibrosis. , 2015, International journal of clinical and experimental pathology.

[5]  D. Scherman,et al.  SMAD3 and SP1/SP3 Transcription Factors Collaborate to Regulate Connective Tissue Growth Factor Gene Expression in Myoblasts in Response to Transforming Growth Factor β , 2015, Journal of cellular biochemistry.

[6]  H. M. Kok,et al.  Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease , 2014, Nature Reviews Nephrology.

[7]  G. Remuzzi,et al.  Key fibrogenic mediators: old players. Renin–angiotensin system , 2014, Kidney international supplements.

[8]  A. Eddy.  Overview of the cellular and molecular basis of kidney fibrosis , 2014, Kidney international supplements.

[9]  N. Robles,et al.  Renin–Angiotensin System Blocking Drugs , 2014, Journal of cardiovascular pharmacology and therapeutics.

[10]  C. Mei,et al.  Kruppel-Like Factor 15 Modulates Renal Interstitial Fibrosis by ERK/MAPK and JNK/MAPK Pathways Regulation , 2013, Kidney and Blood Pressure Research.

[11]  Xiyun Ye,et al.  Both ERK/MAPK and TGF-Beta/Smad Signaling Pathways Play a Role in the Kidney Fibrosis of Diabetic Mice Accelerated by Blood Glucose Fluctuation , 2013, Journal of diabetes research.

[12]  R. Mason.  Fell‐Muir lecture: connective tissue growth factor (CCN2) – a pernicious and pleiotropic player in the development of kidney fibrosis , 2013, International journal of experimental pathology.

[13]  E. Jaimes,et al.  Role of the Transcription Factor Erythroblastosis Virus E26 Oncogen Homolog-1 (ETS-1) as Mediator of the Renal Proinflammatory and Profibrotic Effects of Angiotensin II , 2012, Hypertension.

[14]  Li Zhou,et al.  Angiotensin II increases CTGF expression via MAPKs/TGF-β1/TRAF6 pathway in atrial fibroblasts. , 2012, Experimental cell research.

[15]  J. Leenders,et al.  Repression of Cardiac Hypertrophy by KLF15: Underlying Mechanisms and Therapeutic Implications , 2012, PloS one.

[16]  Josef Coresh,et al.  Chronic kidney disease , 2012, The Lancet.

[17]  G. Wolf,et al.  Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. , 2011, Journal of the American Society of Nephrology : JASN.

[18]  C. Mei,et al.  Low-protein diet supplemented with ketoacids reduces the severity of renal disease in 5/6 nephrectomized rats: a role for KLF15. , 2011, Kidney international.

[19]  G. Remuzzi,et al.  A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis , 2011, Kidney international.

[20]  V. Yang,et al.  Mammalian Krüppel-like factors in health and diseases. , 2010, Physiological reviews.

[21]  S. Schwartz,et al.  Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[22]  H. Lan,et al.  Angiotensin II Induces Connective Tissue Growth Factor and Collagen I Expression via Transforming Growth Factor–&bgr;–Dependent and –Independent Smad Pathways: The Role of Smad3 , 2009, Hypertension.

[23]  J. Mehta,et al.  Deletion of LOX-1 attenuates renal injury following angiotensin II infusion. , 2009, Kidney international.

[24]  J. Song,et al.  Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. , 2008, Transplantation proceedings.

[25]  G. Wolf,et al.  Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. , 2006, Kidney international.

[26]  Saptarsi M. Haldar,et al.  Abstract 1219: The Kruppel-like factor KLF15 inhibits connective tissue growth factor (CTGF) expression in cardiac fibroblasts. , 2006 .

[27]  J. Koo.  Renal Interstitial Fibrosis and Angiotensin Inhibition , 2006, Electrolyte & blood pressure : E & BP.

[28]  K. Nakao,et al.  Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. , 2004, Journal of the American Society of Nephrology : JASN.

[29]  A. Yndestad,et al.  Connective tissue growth factor--a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. , 2004, Journal of molecular and cellular cardiology.

[30]  S. Hong,et al.  Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. , 2003, Biochemical and biophysical research communications.

[31]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[32]  C. Heldin,et al.  The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling. , 2000, Nucleic acids research.